Prevalence and Risk Factors of Thyroid Dysfunction in Older Adults in the Community

Nermin Diab1,2, Natalie R. Daya1,2, Stephen P. Juraschek3, Seth S. Martin2,4, John W. McEvoy2,5,6, Ulla T. Schultheiss7,8, Anna Köttgen3,7 & Elizabeth Selvin1,2

Prevalence estimates and evidence informing treatment targets for thyroid dysfunction largely come from studies of middle-aged adults. We conducted a cross-sectional analysis to determine the prevalence of thyroid dysfunction and risk factors for abnormal thyroid tests in participants aged ≥65 in the Atherosclerosis Risk in Communities (ARIC) study (N = 5,392). We measured serum concentrations of triiodothyronine (T3), free thyroxine (FT4), thyroid peroxidase antibody (Anti-TPO), and thyroid stimulating hormone (TSH). In this population (58% women, 22% black), 17% reported medication use for thyroid dysfunction. Among those not on treatment, the prevalence of overt and subclinical hypothyroidism was 0.82% and 6.06%, respectively. Overt and subclinical hyperthyroidism affected 0.26% and 0.78%, respectively. Multivariable adjusted TSH, FT4 and T3 levels were 25%, 1.3% and 3.9% lower in blacks compared to whites, respectively. Men were less likely to be anti-TPO positive compared to women (p < 0.001). Former and never smoking were associated with lower T3 and FT4 levels compared to current smoking. The prevalence of thyroid dysfunction in older adults is nearly 25%. Multiple illnesses can interact to contribute to declines in health. Additional attention to thyroid dysfunction and screening in this age group is recommended.

Thyroid dysfunction is one of the most common endocrine disorders seen in clinical practice. The prevalence of thyroid dysfunction varies by age, sex, race/ethnicity, and geographically through variations in dietary iodine intake1,2. Abnormal thyroid function has important ramifications on health outcomes pertinent to older adults, including cardiovascular arrhythmia, metabolism, bone health, and mental health3–7.

Current estimates of the prevalence of thyroid dysfunction are largely derived from data in predominantly white middle-aged populations8–10. There are limited available data on the prevalence of thyroid dysfunction in older adults. Furthermore, some studies have shown that the TSH distribution shifts to higher values with increasing age suggesting that a universal treatment target may not be appropriate for all ages11,12. Currently, in clinical practice, guidelines recommend the same cut-points for thyroid hormones irrespective of age, race, or sex13,14.

Little is known about risk factor associations for thyroid dysfunction and correlates of the individual thyroid hormones in an older adult population. While multiple studies have examined associations of race, sex, BMI, dyslipidemia, heart rate, glycemic control, kidney function and smoking with thyroid hormone levels in middle-aged cohorts6,9,10,12,15–18, few studies have addressed these associations exclusively in an older adult population19,20.

In light of the above, the objectives of this study were to (1) investigate the prevalence of thyroid dysfunction in an older community-based U.S. population, (2) better understand demographic and clinical risk factors for thyroid dysfunction in this older age group, and (3) examine the relationship between serum concentrations of triiodothyronine (T3), free thyroxine (FT4), thyroid peroxidase antibody (anti-TPO), and thyroid stimulating hormone (TSH) with demographic and clinical risk factors.
Table 1. Prevalence of thyroid dysfunction, ARIC Visit 5 (2011–2013). *P values were calculated using Chi-square analysis.

| Age (%) | P-value* | Sex (%) | Race (%) | P-value |
|---------|----------|---------|----------|---------|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
| 65–70 | 72.24 ± 5.01 | 65–70 | 72.24 ± 6.00 | 65–70 | 72.24 ± 5.18 |
| 71–75 | 78.09 | 71–75 | 78.09 | 71–75 | 78.09 |
| 76–80 | 70.66 | 76–80 | 70.66 | 76–80 | 70.66 |
| 80+ | 69.59 | 80+ | 69.59 | 80+ | 69.59 |
| P-value | 0.008 | <0.001 | 0.008 | <0.001 | 0.008 |
| TSH (mIU/L) | TSH (mIU/L) | TSH (mIU/L) | TSH (mIU/L) | TSH (mIU/L) |
| 25.0–29.9 | 75.20 | 25.0–29.9 | 75.20 | 25.0–29.9 | 75.20 |
| 30.0+ | 74.68 | 30.0+ | 74.68 | 30.0+ | 74.68 |
| P-value | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| BMI (kg/m²) (%) | BMI (kg/m²) (%) | BMI (kg/m²) (%) | BMI (kg/m²) (%) | BMI (kg/m²) (%) |
| <25.0 | 75.41 | <25.0 | 75.41 | <25.0 | 75.41 |
| 25.0–29.9 | 75.20 | 25.0–29.9 | 75.20 | 25.0–29.9 | 75.20 |
| 30.0+ | 74.68 | 30.0+ | 74.68 | 30.0+ | 74.68 |
| P-value | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |

Results

Among the 5,392 participants, using the ARIC defined (or Roche defined) cut-offs, the prevalence of hypothyroidism was 23.78% (28.90%) and the prevalence of hyperthyroidism was 1.13% (0.36%). Among those with hypothyroidism and hyperthyroidism, 71.06% (56.13%) and 9.68% (30%), respectively, were treated previously. The prevalence of euthyroidism in untreated participants was 82.97% (82.97%). Among those with hypothyroidism and hyperthyroidism, 6.06% (10.5%), overt hypothyroidism was 0.26% (0.07%), subclinical hypothyroidism was 0.78% (0.18%) and euthyroidism was 75.07% (70.74%). The prevalence of participants with treated hypothyroidism or hyperthyroidism was 16.90% (16.22%) and 0.11% (0.11%) respectively (Table 1). Significant differences in prevalence of thyroid dysfunction were observed across participant characteristics. Women had a higher prevalence of treated hypothyroidism compared to males (P < 0.001). Subclinical hypothyroidism and treated hypothyroidism were significantly greater in whites compared to blacks (P < 0.001), while prevalence of subclinical hyperthyroidism was greater in blacks compared to whites (P = 0.002). Higher age and BMI were significantly associated with higher prevalence of subclinical hypothyroidism (P = 0.008 and 0.004 respectively) and treated hypothyroidism (P = 0.001 and 0.049 respectively) (Table 1).

Figures 1–4 show the prevalence of thyroid dysfunction categories by race and age group. Across each age group, the prevalence of subclinical hypothyroidism was higher in whites compared to blacks, with the highest prevalence found in the oldest age group (Fig. 2). The opposite trend was observed for subclinical hyperthyroidism, in which prevalence was greater in blacks compared to whites at any given age group (Fig. 4). No clear racial differences were observed for untreated overt hypothyroidism and untreated overt hyperthyroidism (Figs 1, 3).

In adjusted analyses, TSH levels in black individuals, on average, were 24.7% lower compared to whites (P < 0.001) after adjusting for sex, age, BMI, smoking and drinking history, physical activity and anti-TPO positivity (Table 3). Racial differences were also observed with FT4 and T3, in which levels were 1.32% (P = 0.001) lower in blacks compared to whites, respectively. Both FT4 and T3 were associated with sex, with levels 1.25% (P = 0.009) and 1.75% (P = 0.001) lower in men compared to women respectively. There were no significant independent differences in TSH by sex.

Of all three blood tests, T3 was most strongly associated with age, with levels up to 6.6% lower in individuals older than 80 years of age compared to those ages 65–70. A clear association with age was not observed for FT4. TSH on the other hand, was positively associated with age, with levels up to 9.1% higher in individuals >80 years-old compared to 65–70 years-old (P = 0.003) (Table 2).

T3 levels were 3.5% higher in overweight or obese individuals compared to individuals with a normal BMI. By contrast, FT4 was lower at higher BMI categories. No statistically significant association was observed between TSH and BMI after adjustment.

Smoking status was significantly associated with TSH, FT4, and T3 levels. Current smokers had lower TSH levels compared to former or never smokers (P < 0.001). An inverse relationship was observed for FT4 and T3, in which current smokers had higher levels compared to former or never smokers (P < 0.001). We did not observe
an association of TSH or FT4 with drinking history, although T3 levels were lower for current drinkers as compared to never or former drinkers (P < 0.001) (Table 2).

We observed sex differences in anti-TPO positivity. Men were much less likely to be auto-antibody positive compared to women [OR = 0.59 (0.47, 0.75), P < 0.001]. There were no apparent racial disparities in anti-TPO positivity status [OR = 1.21 (0.93, 1.57), P = 0.15]. Those ages 71–75 were less likely to be auto-antibody positive compared to those ages 65–70 [OR = 0.69 (0.52, 0.91), P = 0.009]. There were no significant adjusted associations with BMI, smoking status, and drinking history (Table 3).
Discussion
In this study, we assessed the prevalence of thyroid dysfunction, and the associations of TSH, FT4, T3 levels and anti-TPO positivity with various demographic and clinical risk factors. Our study has the following important findings: (1) the prevalence of thyroid dysfunction in an older age population was nearly 25% when accounting for treated and untreated thyroid dysfunction categories, (2) significant sex and racial differences were observed in subclinical hypothyroidism, subclinical hyperthyroidism, and treated hypothyroidism in this age group, (3) significantly lower TSH, FT4 and T3 levels were observed in older males and older black individuals, and (4) thyroid hormone levels were associated with clinical risk factors including smoking history, and BMI category.

Data from the Third National Health and Nutrition Examination Survey (NHANES III) conducted from 1988–1994 in individuals aged 12 and older and representative of the general U.S. population found that approximately 4.6% had undiagnosed hypothyroidism (0.3% clinical and 4.3% subclinical) and 1.3% had undiagnosed hyperthyroidism (0.5% clinical and 0.7% subclinical). This survey also observed the prevalence of anti-TPO positivity and TSH concentrations to be greater in females, increase with age, and greater in whites and Mexican Americans compared to blacks10. In our study of an older population, we observed a higher prevalence of undiagnosed hypothyroidism (6.88%, 0.82% overt and 6.06% subclinical) and a smaller prevalence of undiagnosed hyperthyroidism (1.04%, 0.26% overt and 0.78% subclinical). We did observe higher levels of TSH in white participants, and men were less likely to have anti-TPO positivity compared to women. Racial disparities in thyroid hormone levels were associated with clinical risk factors including smoking history, BMI category.

In this study, we assessed the prevalence of thyroid dysfunction, and the associations of TSH, FT4, T3 levels and anti-TPO positivity with various demographic and clinical risk factors. Our study has the following important findings: (1) the prevalence of thyroid dysfunction in an older age population was nearly 25% when accounting for treated and untreated thyroid dysfunction categories, (2) significant sex and racial differences were observed in subclinical hypothyroidism, subclinical hyperthyroidism, and treated hypothyroidism in this age group, (3) significantly lower TSH, FT4 and T3 levels were observed in older males and older black individuals, and (4) thyroid hormone levels were associated with clinical risk factors including smoking history, and BMI category.

Figure 4. Prevalence of Subclinical Hyperthyroidism by race and age group.

Limitations of our study include the cross-sectional design, while ideal for establishing prevalence, we are unable to establish temporality of the observed risk factor associations. Furthermore, this study does not account for the general variability of thyroid function tests in an individual, and there is a possibility that some patients with transient thyroid function tests changes have been misclassified due to the cross-sectional design. As our study used a community-based population, power was limited for some analyses, especially for hyperthyroidism (n = 56 in our study population). Although we adjusted for multiple demographic and clinical risk factors in our analyses, as with any observational study, residual confounding may be a concern.
Table 2. Adjusted Risk Factor Associations for TSH, FT4 and T3. *Adjusted for age category, sex and race; †Adjusted for variables in Model 1 plus BMI category, smoking history, drinking history, physical activity, prevalent CVD and Anti-TPO Positivity. C P Value < 0.05.

The strengths of our study include a large, well-characterized, community-based sample of older adults including a large number of blacks (21.6%), and individuals greater that 80 years-old (N = 993), which are populations that are often underrepresented. The comprehensive panel of thyroid tests and information on thyroid medications at the time of the study further adds to the strength of our analysis.

Our study demonstrated a high prevalence of thyroid dysfunction in an older, community-based population, which is higher than the previously reported prevalence of thyroid dysfunction in community-based studies with younger and middle-aged populations. Furthermore, our study demonstrated that the prevalence of undiagnosed hypothyroidism in older individuals is higher than what has previously been reported. There were clear differences by sex and race, with older women having a higher prevalence of treated hypothyroidism compared to older men, and older whites having a higher prevalence of subclinical hypothyroidism and treated hypothyroidism compared to older blacks. The prevalence of subclinical hyperthyroidism was greater in blacks compared to whites.

With rising life expectancies and aging populations, it is increasingly important to understand variations in thyroid dysfunction in older individuals and their association with risk factors encountered in daily clinical practice. Our study demonstrated a thyroid dysfunction prevalence of nearly 25% in older individuals. This high prevalence sheds a light on the potential for the underappreciation of both overt and subclinical thyroid diseases, which can have substantial effects on the management and treatment of older patients who might also present with other complex comorbidities. Our results call for greater awareness of thyroid dysfunction, and the potential need for more thyroid function screening in this age group.

Methods

We conducted a cross-sectional study using data from the Atherosclerosis Risk in Communities (ARIC) study. This is a prospective epidemiologic cohort that began with 15,792 individuals recruited between 1987–1989 from 4 study centers in the United States (Forsyth County, North Carolina, Jackson, Mississippi, Minneapolis, Minnesota, and Washington County, Maryland)36. The current study involves visit 5 (2011–2013). All study participants provided informed consent at each study visit.
There were 6,538 participants, all aged 65 or older, who attended visit 5. We excluded individuals who were neither white nor African American, and those who were missing any covariate of interest. Our final study population included 5,392 participants who had complete data for all variables of interest. In regression analyses of thyroid hormone concentrations, we excluded individuals receiving current treatment for either hypothyroidism or hyperthyroidism (n = 917).

The ARIC study has been approved by the Institutional Review Boards (IRB) at all participating institutions: University of North Carolina at Chapel Hill IRB, Wake Forest University IRB, Johns Hopkins University IRB, University of Minnesota IRB and University of Mississippi Medical Center IRB. Written informed consent was obtained from all study participants. All methods were carried out in accordance with the relevant guidelines and regulations for human subject research, in accordance with the Declaration of Helsinki.

**Laboratory measurements.** Thyroid parameters were measured in 2012–2013 at the University of Minnesota in stored serum samples originally collected from ARIC participants at visit 5. TSH, FT4, T3 and anti-TPO were measured in serum on a Roche e411 Immunoassay Analyzer (Roche Diagnostics Corporation, Indianapolis, IN). The inter-assay coefficients of variation for the thyroid hormones were: TSH, 3.6% at a mean concentration of 0.208 mIU/L; FT4, 4.9% at a mean concentration of 1.09 ng/dL; T3, 6.7% at a mean concentration of 364.5 ng/dL; and, anti-TPO, 9.1% at a mean concentration of 133 IU/mL.

**Study variable definitions.** Using ARIC defined cut-offs, the following definitions for each thyroid dysfunction category were used for the main analysis as has been done in previous ARIC papers. For comparison, we also used manufacturer (Roche) defined cut-offs to define prevalence of the various thyroid conditions. Overt hyperthyroidism: serum TSH < 0.56 mIU/L and FT4 > 1.4 ng/dL (Roche, TSH < 0.27 mIU/L and FT4 > 1.7 ng/dL), overt hypothyroidism: serum TSH > 5.1 mIU/L and FT4 < 0.85 ng/dL (Roche, TSH > 4.2 mIU/L and FT4 < 0.93 ng/dL), subclinical hyperthyroidism: normal FT4 (0.85–1.4 ng/dL) and serum TSH below lower limit of reference range < 0.56 mIU/L (TSH < 0.27 mIU/L and 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL), subclinical hypothyroidism: normal FT4 (0.85–1.4 ng/dL) and serum TSH higher than upper limit of reference range > 5.1 mIU/L (TSH > 4.2 mIU/L and 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL) (Table 4). The presence of anti-TPO antibodies was defined as serum concentration ≥ 34 IU/mL. Treated thyroid dysfunction was defined as self-reported diagnosis by a physician and currently taking medication for the condition.

**BMI was calculated as kg/m². Smoking history was defined as never, former, or current smoker. Alcohol use was defined as never, former, or current drinker.**

**Statistical analysis.** We evaluated the prevalence of thyroid dysfunction categories according to age, 65–70 (n = 1,018), 71–75 (n = 1,957), 76–80 (n = 1,424), 80+ (n = 993), sex, men (n = 2,257), women (n = 3,135), race, white (n = 4,227), black (n = 1,165), BMI category, normal weight (n = 1,387), overweight (n = 2,149), obese

| Variable                  | Model 1* OR (95%CI) | P Value | Model 2† OR (95%CI) | P Value |
|---------------------------|---------------------|---------|---------------------|---------|
| Sex                       | Male (Female Reference) | 0.55 [0.45,0.69] | <0.001 | 0.59 [0.47,0.75] | <0.001 |
| Race                      | Black (White Reference) | 1.19 [0.94,1.49] | 0.146 | 1.21 [0.93,1.57] | 0.152 |
| Age                       | 65–70 (Reference) | 1.00 | --- | 1.00 | --- |
|                            | 71–75 | 0.72 [0.55,0.94] | 0.016 | 0.69 [0.52,0.91] | 0.009 |
|                            | 76–80 | 0.81 [0.61,1.08] | 0.16 | 0.80 [0.59,1.08] | 0.15 |
|                            | 80+   | 0.73 [0.53,1.01] | 0.059 | 0.73 [0.51,1.03] | 0.069 |
| BMI (Kg/m²)               | <25.0 (Reference) | 1.00 | --- | 1.00 | --- |
|                            | 25.0–29.9 | 0.88 [0.69,1.13] | 0.315 | 0.92 [0.71,1.19] | 0.52 |
|                            | 30.0+  | 0.86 [0.66,1.11] | 0.241 | 0.92 [0.70,1.22] | 0.56 |
| Smoking History            | Current Smoker (Reference) | 1.00 | --- | 1.00 | --- |
|                            | Former Smoker | 0.87 [0.57,1.32] | 0.506 | 0.85 [0.56,1.30] | 0.456 |
|                            | Never Smoker | 0.99 [0.65,1.51] | 0.955 | 0.91 [0.59,1.41] | 0.669 |
| Drinking History           | Current Drinker (Reference) | 1.00 | --- | 1.00 | --- |
|                            | Former Drinker | 0.93 [0.72,1.21] | 0.604 | 0.95 [0.73,1.24] | 0.73 |
|                            | Never Drinker | 1.20 [0.92,1.56] | 0.184 | 1.17 [0.88,1.56] | 0.28 |

Table 3. Adjusted Odds Ratios (95% Confidence Intervals) of Anti-TPO Positivity ≥ 34 IU/ml. *Adjusted for age category, sex and race, †Adjusted for variables in Model 1 plus BMI category, smoking history, drinking history, physical activity, and prevalent CVD.
(n = 1,856), using ARIC defined cut-off points. P-values for differences between thyroid dysfunction categories were obtained using chi-squared analysis compared to the euthyroid group. Distributions of continuous variables were assessed for normality using Shapiro-Wilk test and Kernel plots. Because the distribution of some continuous variables was not normal, natural log-transformation was performed to TSH, FT4, and T3, in which normality was approached after transformation.

We used multivariable linear regression to examine the association between log-transformed TSH, FT4, T3 and various demographic and clinical risk factors including sex, race, age, BMI, smoking and drinking history. Effect estimates from the multivariable linear models and their corresponding 95% confidence intervals were converted to percent change in TSH, FT4, or T3 levels for the presence of each categorical and continuous predictor variable by exponentiation of the effect estimate, subtracting 1, and multiplying by 100, i.e. 100 × (e^β − 1). We used logistic regression to examine the association of anti-TPO positivity and the same demographic and clinical risk factors. Odds ratios and their corresponding 95% confidence intervals were calculated.

We evaluated two models to assess for these associations after adjustment for sex, race and age (model 1) and additionally BMI, smoking history, drinking history, physical activity level, and diagnosis of cardiovascular disease (model 2) for each of TSH, FT4, T3 and anti-TPO positivity. All tests performed were two tailed and statistical significance was determined to be at P < 0.05.

All statistical analyses where performed using Stata/SE 14 (StataCorp, College Station, TX).

### Data Availability

The datasets generated and analysed during the current study are available from the corresponding author, Dr. Elizabeth Selvin (eselvin@jhu.edu), on reasonable request. Most ARIC data can be also obtained from BioLINCC, a repository maintained by the National Heart, Lung, and Blood Institute. The BioLINCC website includes detailed information about the available data and the process to obtain such data.

### References

1. Herman, E., Khattak, R. M., Nauck, M., Cordova, C. M. & Volske, H. Shaft of the TSH reference range with improved iodine supply in Northeast Germany. *Eur J Endocrinol* 172, 261–267, https://doi.org/10.1530/EJE-14-0898 (2015).
2. Meisinger, C. et al. Geographic variations in the frequency of thyroid disorders and thyroid peroxidase antibodies in persons without former thyroid disease within Germany. *Eur J Endocrinol* 167, 363–371, https://doi.org/10.1530/EJE-12-0111 (2012).
3. Biondi, B. & Cooper, D. S. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev* 29, 76–131, https://doi.org/10.1210/er.2006-0043 (2008).
4. Cooper, D. S. & Biondi, B. Subclinical thyroid disease. *Lancet* 379, 1142–1154, https://doi.org/10.1016/S0140-6736(11)60276-6 (2012).
5. Juarez-Cedillo, T. et al. Prevalence of thyroid dysfunction and its impact on cognition in older mexican adults: (SADEM study). *J Endocrinol Invest* 40, 945–952, https://doi.org/10.1007/s40618-017-0654-6 (2017).
6. Geppa, M., Betts, G. & Dimitriadis, G. Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. *J Lipids* 2011, 575840, https://doi.org/10.1155/2011/575840 (2011).
7. Tan, Z. S. et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. *Arch Intern Med* 168, 1514–1520, https://doi.org/10.1001/archinte.2008.1514 (2008).
8. Garmendia Madariaga, A., Santos Palacios, S., Guillon-Grima, F. & Galofre, J. C. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. *J Clin Endocrinol Metab* 99, 923–931, https://doi.org/10.1210/jc.2013-2409 (2014).
9. Canaris, G. J., Manowitz, N. R., Mayor, G. & Ridgway, E. C. The Colorado thyroid disease prevalence study. *Archives of Internal Medicine* 160, 526–534 (2000).
10. Hollowell, J. G. et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *The Journal of Clinical Endocrinology & Metabolism* 87, 489–499, https://doi.org/10.1210/jcem.87.2.81882 (2002).
11. Bremer, A. P. et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. *The Journal of clinical endocrinology and metabolism* 97, 1554–1562, https://doi.org/10.1210/jc.2011-3020 (2012).
12. Vaidivelu, T., Donnan, P. T., Murphy, M. J. & Leese, G. P. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). *The Journal of clinical endocrinology and metabolism* 98, 1147–1153, https://doi.org/10.1210/jc.2012-3191 (2013).
13. Jonklaas, J. et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. *Thyroid* 24, 1670–1751, https://doi.org/10.1089/thy.2014.0028 (2014).
14. Ross, D. S. et al. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* 26, 1343–1421, https://doi.org/10.1089/thy.2016.0229 (2016).
15. Belin, R. M., Astor, B. C., Powe, N. R. & Ladenson, P. W. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). *The Journal of Clinical Endocrinology & Metabolism* 89, 6077–6086, https://doi.org/10.1210/jc.2004-0431 (2004).
16. Diez, J. J., Sanchez, P. & Igelias, P. Prevalence of thyroid dysfunction in patients with type 2 diabetes. *Experimental and Clinical Endocrinology & Diabetes* 119, 201–207, https://doi.org/10.1055/s-0031-1271691 (2011).
17. Jorde, R. & Sundsfjord, J. Serum TSH levels in smokers and non-smokers. The 5th Tromso study. *Experimental and clinical endocrinology & diabetes* 114, 343–347, https://doi.org/10.1055/s-0026-924264 (2006).

### Table 4. Summary of ARIC and Roche cut-points for thyroid dysfunction.

|                      | Overt Hyperthyroidism | Subclinical Hyperthyroidism | Overt Hyperthyroidism | Subclinical Hyperthyroidism |
|----------------------|-----------------------|-----------------------------|-----------------------|-----------------------------|
| Roche cutoff         | TSH > 4.2 mIU/L & FT4 < 0.93 ng/dL | TSH > 4.2 mIU/L & 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL | TSH < 0.27 mIU/L & FT4 > 1.7 ng/dL | TSH < 0.27 mIU/L & 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL |
| ARIC cutoff          | TSH > 5.1 mIU/L & FT4 < 0.85 ng/dL | TSH > 5.1 mIU/L & 0.85 ng/dL ≤ FT4 ≤ 1.4 ng/dL | TSH < 0.56 mIU/L & FT4 > 1.4 ng/dL | TSH < 0.56 mIU/L & 0.85 ng/dL ≤ FT4 ≤ 1.4 ng/dL |

|                      | Overt Hyperthyroidism | Subclinical Hyperthyroidism | Overt Hyperthyroidism | Subclinical Hyperthyroidism |
|----------------------|-----------------------|-----------------------------|-----------------------|-----------------------------|
| Roche cutoff         | TSH > 4.2 mIU/L & FT4 < 0.93 ng/dL | TSH > 4.2 mIU/L & 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL | TSH < 0.27 mIU/L & FT4 > 1.7 ng/dL | TSH < 0.27 mIU/L & 0.93 ng/dL ≤ FT4 ≤ 1.7 ng/dL |
| ARIC cutoff          | TSH > 5.1 mIU/L & FT4 < 0.85 ng/dL | TSH > 5.1 mIU/L & 0.85 ng/dL ≤ FT4 ≤ 1.4 ng/dL | TSH < 0.56 mIU/L & FT4 > 1.4 ng/dL | TSH < 0.56 mIU/L & 0.85 ng/dL ≤ FT4 ≤ 1.4 ng/dL |

(n = 1,856), using ARIC defined cut-off points. P-values for differences between thyroid dysfunction categories were obtained using chi-squared analysis compared to the euthyroid group. Distributions of continuous variables were assessed for normality using Shapiro-Wilk test and Kernel plots. Because the distribution of some continuous variables was not normal, natural log-transformation was performed to TSH, FT4, and T3, in which normality was approached after transformation.
18. Schultheiss, U. T. et al. Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, https://doi.org/10.1093/ndt/gfw301 (2016).
19. Gopinath, B. et al. Type 2 diabetes does not predict incident thyroid dysfunction in the elderly. Diabetes research and clinical practice 82, e11–e13, https://doi.org/10.1016/j.diabres.2008.08.017 (2008).
20. Jonklaas, J. & Razvi, S. Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers. Lancet Diabetes Endocrinol 7, 473–483, https://doi.org/10.1016/S2213-8587(18)30371-1 (2019).
21. Schectman, J. M., Kallenberg, G. A., Hirsch, R. P. & Shumacher, R. J. Report of an association between race and thyroid stimulating hormone level. American Journal of Public Health 81, 505–506 (1991).
22. D’angelo, S. A. Simultaneous effects of estradiol on TSH secretion and adrenocortical function in male and female rats. Endocrinology 82, 1033–1041, https://doi.org/10.1210/endo-82-5-1033 (1968).
23. Mazer, N. A. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid: official journal of the American Thyroid Association 14(Suppl 1), S27–34, https://doi.org/10.1089/105072504323024561 (2004).
24. Veltri, F. et al. Prevalence of thyroid dysfunction and autonomy in the older population and implications of age-specific reference ranges. Clinica chimica acta; international journal of clinical chemistry 465, 34–39, https://doi.org/10.1016/j.cca.2016.12.008 (2017).
25. Taylor, P. N. et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA internal medicine 174, 32–39, https://doi.org/10.1001/jamainternmed.2013.11312 (2014).
26. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.
27. Martin, S. S. et al. Thyroid Function, Cardiovascular Risk Factors, and Incident Atherosclerotic Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. The Journal of clinical endocrinology and metabolism 102, 3306–3315, https://doi.org/10.1210/jc.2017-00986 (2017).
28. NIH/NHLBI Biologic Specimen and Data Repository Information Coordinating Center, https://biolincc.nhlbi.nih.gov/ (1987).

Acknowledgements
The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700003I, HHSN268201700004I, HHSN268201700005I, HHSN268201700004I, HHSN268201700002I). This research was also supported by NIH/NIDDK grants 2R01DK089174 and K24DK106414 to Dr. Selvin, and by the CRC 1140 of the German Research Foundation (Dr. Schultheiss and Dr. Köttgen). Dr. Schultheiss was supported by a scholarship from the Else Kroener Fresenius Foundation (NAKSYS). Dr. Juraschek was supported by a K23HL135273. Reagents for the thyroid function tests were donated by the Roche Diagnostics Corporation. The authors thank the staff and participants of the ARIC study for their important contributions.

Author Contributions
N.D., N.R.D. and E.S. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. N.D. performed analyses, interpreted results and wrote the manuscript. N.R.D. performed analyses and interpreted results. E.S. provided substantial guidance in study design, results interpretation and manuscript revisions. N.D., N.R.D., E.S., S.P.J., S.S.M., J.W.M., U.T.S. and A.K., provided subject area expertise and reviewed the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019